One of the most controversial aspects of Neuroendocrine Tumours (NETs) is the ‘benign vs malignant’ question. It’s been widely debated, and it frequently patrols the various patient forums and other social media platforms. It raises emotions and it triggers many responses ….. at least from those willing to engage in the conversation. At best, this issue can cause confusion, at worst, it might contradict what new patients have been told by their physicians (….or not been told). This post will not cover Neuroendocrine Carcinoma which by standard cancer nomenclature definition is malignant.
Any standard cancer nomenclature definition of the word ‘tumour’ will confirm the definition of the word tumour means it can either be benign or malignant. The other connotation of ‘benign’ is that some might say it is not a cancer. But let’s be clear, Neuroendocrine Tumours are cancer.


However, and while I’m sure there are some NETs which might be academically described as ‘benign’, the key statement to explain any slow-growing or indolent NET is that they all have malignant potential – thus why surveillance and follow-up are really important. This was the key factor in the changes found in the 2010 Digestive System World Health Organisation (WHO) classification system from the previous ‘flaky’ version. This reinforcement of the malignant potential of all NETs was duplicated in the recent 2017 Endocrine System and 2019 Digestive System equivalents, which is now proposed as a classification scheme for all NETs (see below).
“Carcinoid”
Of course, we are not helped by the continued use of the term Carcinoid which decodes to ‘Carcinoma Like’ – that is potentially regressing the work of those specialists who are trying to undo over 100 years of complacency in the medical world (….. and it’s not really the type of awareness we need). The word is gradually being erased from NET nomenclature and the recent 2018 proposal by the International Agency for Research on Cancer (IARC) and WHO NET expert consensus panel to ditch it from the remaining versions of out of date WHO classifications (e.g. Pulmonary/Lung, Pituitary, Head & Neck, Genito-urinary, Adrenal and Paraganglia, Skin), may be the final nail in the coffin for Carcinoid. RIP Carcinoid. This also supports our awareness issues with the media reporting the wrong cancer types based on anatomy of the primary tumour.
Dear Doctors, Patient Advocates, Patients ….. Please stop using the word, it’s not helpful!
I’ve lost count of the stories from Neuroendocrine Cancer patients who have been told their tumour was benign but then returned to specialists at a later stage with incurable and metastatic cancer. There are doctors who clearly do not understand NETs and/or are not aware of the changes in WHO classification schemes from 2010 onwards. Sure, some will prove to be ‘benign’ in nature and may not cause many issues but any Ki-67 below 3% is a formal cancer grade of a Neuroendocrine Neoplasm. I accept that it’s currently difficult to work out which cases will turn more aggressive and when, thus why surveillance and follow-up are really important and also why patients should be seeing doctors who understand NETs. More sensitive molecular markers assisting doctors in decision-making will be welcome at some point in the future. Worth also noting that many slow-growing and indolent tumours can still often produce troublesome NET syndromes.
I’ve even heard one patient story where it was claimed a doctor called a metastatic NET case benign! Any standard cancer nomenclature definition of ‘benign’ on any respectable cancer site will include the statement that they do not spread to other parts of the body. The NET patient world is full of slow-growing Grade 1 Stage 4 patients. By dint of the stage number, they’re all malignant.
Read more detail in the articles below as these issues are inextricably linked.
I’m sure there are scenarios in all cancers where tumours can be benign and will never harm the person but if a doctor says you have a Neuroendocrine Tumour and not to worry because it’s benign, ask questions. Start with “how do you know it will never turn malignant” and “what will be done going forward to check”. This is particularly important in cases of Small Intestine and Pancreatic NETs where there is a greater risk of spread than other NET types.
I also acknowledge that many slow-growing localised NETs have much less prevalence for spread, i.e. Appendiceal NET, Rectal NET, and to a certain extent atypical Lung NET. Epidemiological data confirm these have less risk of spreading and there are curative scenarios in completed removing the localised primary with the right margins.




Thanks for listening
Click here and answer all questions to join my private Facebook group
Thanks for reading.
Ronny
Disclaimer
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
- Spotlight: Potassium in Neuroendocrine Tumours (NETs)
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If… Read more: Spotlight: Potassium in Neuroendocrine Tumours (NETs) - Spotlight: Magnesium in Neuroendocrine Tumours (NETs)
Before you read thisThis information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you… Read more: Spotlight: Magnesium in Neuroendocrine Tumours (NETs) - Ronny Allan’s Newsletter covering July 2026
Summary of July 2026 on RonnyAllan.NET July was similar to the other months of this year but views down on the previous two months due to 50% of the month spent on holiday. Still a reasonable blog performance. Other key targets met were three more editions of the Spotlight series on vitamins and minerals. See… Read more: Ronny Allan’s Newsletter covering July 2026 - 16 years since diagnosis, I’m still here

I finally made 16 years since I was diagnosed on 26th July 2010. A milestone I was not certain at the time I would reach. However, as things progressed, as treatment was administered, and as I got used to living with Neuroendocrine Cancer, I eventually became more confident this was a possibility with the help […]
- Spotlight on Cushing’s Syndrome in Neuroendocrine Neoplasms
Intro Cushing’s syndrome is one of the most challenging hormonal complications seen in people with neuroendocrine neoplasms (NENs). It can be subtle, severe, or even life‑threatening — and it is often misunderstood. Many patients struggle for months or years before receiving a correct diagnosis, partly because the symptoms overlap with everyday conditions such as weight… Read more: Spotlight on Cushing’s Syndrome in Neuroendocrine Neoplasms - 14th July 2026 – Ronny Allan hits 3 million blog views!
Today, 14th July 2026, I can confirm the 3 million views milestone has been reached. MASSIVE THANKS to you guys for reading and sharing. When I first set up this blog in April 2014, it was just to help spread awareness (….and collect a few pennies) whilst I was walking the 84 miles of… Read more: 14th July 2026 – Ronny Allan hits 3 million blog views! - Spotlight: Zinc in Neuroendocrine Tumours (NETs)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have… Read more: Spotlight: Zinc in Neuroendocrine Tumours (NETs) - Neuroendocrine Tumours – Iron
Disclaimer: This Spotlight provides general educational information about Iron. It is not a substitute for medical advice. Individual needs vary, particularly for those with conditions affecting digestion, absorption, or chronic blood loss. Always consult your medical team before making changes to supplements or nutrition. Before I knew I had metastatic Neuroendocrine Tumours, I was diagnosed… Read more: Neuroendocrine Tumours – Iron - Ronny Allan’s Newsletter covering June 2026
Headline – half yearly point bonus edition Summary of June 2026 on RonnyAllan.NET June was similar to the other months of this year but slightly down on the previous two months due to holiday. Still a strong blog performance. Other key targets met were three more editions of the Spotlight series on primary NET types (colon, thymic… Read more: Ronny Allan’s Newsletter covering June 2026 - Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over… Read more: Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey - Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the… Read more: Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET - SYHX2008: A New Self‑Injectable subcutaneous Long‑acting Octreotide on the Horizon for NETs
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the… Read more: SYHX2008: A New Self‑Injectable subcutaneous Long‑acting Octreotide on the Horizon for NETs - Small tumours – big impact
Many Neuroendocrine Tumours are small. Not my words but I first discovered the term in 2021 when reading the words of Dr Mark Lewis, Oncologist and NET Patient. He himself, was citing this term referencing back to giants in the world of NETs over many decades. There was a seminal lecture entitled “An Odyssey in… Read more: Small tumours – big impact - The Invisibility of Neuroendocrine Tumours (NET) – an awareness post by Ronny Allan
“Invisible cancer” typically refers to malignancies that evade early detection or disguise themselves as other common, non-life-threatening ailments. This term is very frequently associated with Neuroendocrine Tumours which are very often difficult to spot on standard imaging and blood tests. When I was diagnosed, I didn’t even feel ill. It was therefore a bit of… Read more: The Invisibility of Neuroendocrine Tumours (NET) – an awareness post by Ronny Allan
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.



I was incensed when a locum that I was seeing at our local hospital about an unrelated issue questioned whether or not I actually had cancer! Yes, my NETS is cancer! Why in the world would I claim to have cancer if I didn’t?
I feel this is the MOST important issue that I’ve encountered, my father encountered and has left some young people in the serious position of “inoperable” when their “mets” were discovered after an initial diagnosis of benign. I myself could have easily fallen into this crack in the sidewalk when my local GP and surgeon said first tumor was “benign” . . . But my father’s “benign” tumor came back and killed him when he had mets to his bones. FOLLOW-UP IS EXTREMELY IMPORTANT . . . The reason I’m alive 11 years after first SDHB Deficient tumor diagnosis.